MXPA03001227A - Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. - Google Patents

Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.

Info

Publication number
MXPA03001227A
MXPA03001227A MXPA03001227A MXPA03001227A MXPA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A MX PA03001227 A MXPA03001227 A MX PA03001227A
Authority
MX
Mexico
Prior art keywords
compositions
pyridinamine
cell death
related methods
provides
Prior art date
Application number
MXPA03001227A
Other languages
English (en)
Inventor
Benjamin Daniel
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA03001227A publication Critical patent/MXPA03001227A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invencion provee composiciones farmaceuticas neuroprotectoras que comprenden 2-piridinaminas; esta invencion tambien provee metodos para utilizar estas composiciones para evitar muerte celular isquemica, particularmente muerte celular neuronal, y deducir la probabilidad de muerte celular neuronal en un sujeto debido a un evento traumatico; finalmente esta invencion provee un aparato para administrar a un sujeto las composiciones farmaceuticas de la presente.
MXPA03001227A 2000-08-08 2001-08-06 Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. MXPA03001227A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22379500P 2000-08-08 2000-08-08
PCT/US2001/041565 WO2002011724A2 (en) 2000-08-08 2001-08-06 Neuroprotective 2-pyridinamine compositions and related methods

Publications (1)

Publication Number Publication Date
MXPA03001227A true MXPA03001227A (es) 2004-09-10

Family

ID=22837998

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001227A MXPA03001227A (es) 2000-08-08 2001-08-06 Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.

Country Status (13)

Country Link
US (2) US20020198219A1 (es)
EP (1) EP1317266A2 (es)
JP (1) JP2004510707A (es)
CN (1) CN1635890A (es)
AR (1) AR030140A1 (es)
AU (1) AU2001278206A1 (es)
BR (1) BR0113148A (es)
CA (1) CA2418912A1 (es)
IL (1) IL154267A0 (es)
MX (1) MXPA03001227A (es)
NZ (1) NZ524101A (es)
WO (1) WO2002011724A2 (es)
ZA (1) ZA200301861B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
EP1363702A4 (en) * 2001-01-30 2007-08-22 Cytopia Pty Ltd PROCESS FOR INHIBITING KINASES
CN1890218B (zh) 2003-12-03 2011-08-03 Ym生物科学澳大利亚私人有限公司 微管蛋白抑制剂
PL2402319T3 (pl) 2006-03-31 2018-02-28 Novartis Ag Inhibitory DGAT
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
WO2008128968A1 (en) * 2007-04-19 2008-10-30 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5
GB0821307D0 (en) * 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2013081094A1 (ja) * 2011-11-30 2013-06-06 東レ株式会社 イミダゾ［１，２－ａ］ピリジン誘導体及びその医薬用途
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
US9745328B2 (en) 2013-02-04 2017-08-29 Janssen Pharmaceutica Nv Flap modulators
JP7249950B2 (ja) * 2017-03-27 2023-03-31 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー ヘテロ環化合物
GB201809102D0 (en) * 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
AU2019350717A1 (en) 2018-09-25 2021-05-27 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
CN116940354A (zh) 2020-09-28 2023-10-24 卡都瑞恩医药股份有限公司 稠合的杂芳基化合物及其作为CaMKII抑制剂的用途
EP4366724A2 (en) * 2021-07-09 2024-05-15 CZ Biohub SF, LLC Cdk19-selective inhibitors, and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
KR0138353Y1 (ko) * 1996-12-13 1999-04-01 주식회사부윤테크 일회용 주사기
PL334304A1 (en) * 1996-12-24 2000-02-14 Chugai Pharmaceutical Co Ltd Derivatives of aromatic amines acting as nos inhibitors
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
NZ520241A (en) * 2000-02-25 2004-05-28 F Adenosine receptor modulators

Also Published As

Publication number Publication date
AU2001278206A1 (en) 2002-02-18
EP1317266A2 (en) 2003-06-11
AR030140A1 (es) 2003-08-13
BR0113148A (pt) 2003-07-08
WO2002011724A3 (en) 2002-08-15
CN1635890A (zh) 2005-07-06
IL154267A0 (en) 2003-09-17
WO2002011724A2 (en) 2002-02-14
ZA200301861B (en) 2004-07-07
US20020198219A1 (en) 2002-12-26
NZ524101A (en) 2004-11-26
JP2004510707A (ja) 2004-04-08
US20030225085A1 (en) 2003-12-04
CA2418912A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
MXPA03001227A (es) Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
BE2013C064I2 (es)
MY125978A (en) Admantane derivatives
MY135683A (en) Compositions for improving fertility
AU2003280087A8 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
AP2003002755A0 (en) Guanidinobenzamides as mc4-r agonists
IL140338A0 (en) Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same
NO20024586D0 (no) Metode og preparater for å forhindre hormoninduserte bivirkninger
MXPA03001226A (es) Derivados de 4-pirimidinamina, composiciones farmaceuticas y metodos relacionados.
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
EP1391200A4 (en) DRUG
AU2002236647A1 (en) Method and device for administering medication and/or placebo
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
TN2009000119A1 (en) Combination drug
WO2002072021A3 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
HK1052168A1 (en) N-deacetylthiocolchincine derivatives and pharmaceutical compositions containing them.
AU6814701A (en) Methods and compositions for producing a neurosalutary effect in a subject
GB9930075D0 (en) Medicaments
IL153541A0 (en) The use of 7-hydroxyepiandrosterone for the manufacture of pharmaceutical compositions